Literature DB >> 12161421

Emergence of Staphylococcus aureus (MRSA) with reduced susceptibility to teicoplanin during therapy.

Michael Weinbren, Keith Struthers.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12161421     DOI： 10.1093/jac/dkf110

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  4 in total

1.  Teicoplanin dosing strategy for treatment of Staphylococcus aureus in Korean patients with neutropenic fever.

Authors:  Byung-Jin Ahn; Dong-Seok Yim; Dong-Gun Lee; Jae-Cheol Kwon; Si-Hyun Kim; Su-Mi Choi
Journal:  Yonsei Med J       Date:  2011-07       Impact factor: 2.759

2.  Teicoplanin in patients with acute leukaemia and febrile neutropenia: a special population benefiting from higher dosages.

Authors:  Federico Pea; Pierluigi Viale; Anna Candoni; Federica Pavan; Leonardo Pagani; Daniela Damiani; Marco Casini; Mario Furlanut
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

3.  Effect of hospitalization and antimicrobial therapy on antimicrobial resistance of colonizing Staphylococcus epidermidis.

Authors:  Ariane Knauer; Petra Fladerer; Christina Strempfl; Robert Krause; Christoph Wenisch
Journal:  Wien Klin Wochenschr       Date:  2004-07-31       Impact factor: 1.704

4.  Loading regimen required to rapidly achieve therapeutic trough plasma concentration of teicoplanin and evaluation of clinical features.

Authors:  Masafumi Seki; Kaori Yabuno; Koji Miyawaki; Yoshihiro Miwa; Kazunori Tomono
Journal:  Clin Pharmacol       Date:  2012-11-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.